Literature DB >> 25746798

Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.

Shenli Zhang1, Iain B Tan2, Nur S Sapari3, Heike I Grabsch4, Alicia Okines5, Elizabeth C Smyth5, Toru Aoyama6, Lindsay C Hewitt4, Imran Inam4, Dan Bottomley4, Matthew Nankivell7, Sally P Stenning7, David Cunningham5, Andrew Wotherspoon8, Akira Tsuburaya9, Takaki Yoshikawa6, Richie Soong10, Patrick Tan11.   

Abstract

DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissues has been used in the past to analyze genetic polymorphisms. We evaluated the technical reproducibility of different types of assays for gene polymorphisms using DNA extracted from FFPE material. By using the MassARRAY iPLEX system, we investigated polymorphisms in DPYD (rs1801159 and rs3918290), UMPS (rs1801019), ERCC1 (rs11615), ERCC1 (rs3212986), and ERCC2 (rs13181) in 56 FFPE DNA samples. By using PCR, followed by size-based gel electrophoresis, we also examined TYMS 5' untranslated region 2R/3R repeats and GSTT1 deletions in 50 FFPE DNA samples and 34 DNAs extracted from fresh-frozen tissues and cell lines. Each polymorphism was analyzed by two independent runs. We found that iPLEX biomarker assays measuring single-nucleotide polymorphisms provided consistent concordant results. However, by using FFPE DNA, size-based PCR biomarkers (GSTT1 and TYMS 5' untranslated region) were discrepant in 32.7% (16/49, with exact 95% CI, 19.9%-47.5%; exact binomial confidence limit test) and 4.2% (2/48, with exact 95% CI, 0.5%-14.3%) of cases, respectively, whereas no discrepancies were observed using intact genomic DNA. Our findings suggest that DNA from FFPE material can be used to reliably test single-nucleotide polymorphisms. However, results based on size-based PCR biomarkers, and particularly GSTT1 deletions, using FFPE DNA need to be interpreted with caution. Independent repeated assays should be performed on all cases to assess potential discrepancies.
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25746798      PMCID: PMC4411247          DOI: 10.1016/j.jmoldx.2014.12.001

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  47 in total

Review 1.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

2.  Association of thymidylate synthase polymorphisms with gastric cancer susceptibility.

Authors:  Francesco Graziano; Kazuyuki Kawakami; Go Watanabe; Annamaria Ruzzo; Bostjan Humar; Daniele Santini; Vincenzo Catalano; Rita Ficarelli; Tony Merriman; Simona Panunzi; Enrica Testa; Stefano Cascinu; Italo Bearzi; Giuseppe Tonini; Mauro Magnani
Journal:  Int J Cancer       Date:  2004-12-20       Impact factor: 7.396

3.  The role of CCNH Val270Ala (rs2230641) and other nucleotide excision repair polymorphisms in individual susceptibility to well-differentiated thyroid cancer.

Authors:  Luís S Santos; Bruno C Gomes; Rita Gouveia; Susana N Silva; Ana P Azevedo; Vanessa Camacho; Isabel Manita; Octávia M Gil; Teresa C Ferreira; Edward Limbert; José Rueff; Jorge F Gaspar
Journal:  Oncol Rep       Date:  2013-08-27       Impact factor: 3.906

4.  Glutathione S-transferase (GST) gene polymorphisms, cigarette smoking and colorectal cancer risk among Chinese in Singapore.

Authors:  Woon-Puay Koh; Heather H Nelson; Jian-Min Yuan; David Van den Berg; Aizhen Jin; Renwei Wang; Mimi C Yu
Journal:  Carcinogenesis       Date:  2011-07-29       Impact factor: 4.944

5.  Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.

Authors:  Michele L Cote; Govindaraja Atikukke; Julie J Ruterbusch; Sara H Olson; Shawnita Sealy-Jefferson; Benjamin A Rybicki; Sharon Hensley Alford; Mohammad A Elshaikh; Arthur R Gaba; Daniel Schultz; Ramsi Haddad; Adnan R Munkarah; Rouba Ali-Fehmi
Journal:  Int J Gynecol Cancer       Date:  2012-10       Impact factor: 3.437

6.  Comparison of a multiplexed MassARRAY system with real-time allele-specific PCR technology for genotyping of methicillin-resistant Staphylococcus aureus.

Authors:  M W Syrmis; R J Moser; D M Whiley; V Vaska; G W Coombs; M D Nissen; T P Sloots; G R Nimmo
Journal:  Clin Microbiol Infect       Date:  2011-05-20       Impact factor: 8.067

7.  Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma.

Authors:  T Katoh; N Nagata; Y Kuroda; H Itoh; A Kawahara; N Kuroki; R Ookuma; D A Bell
Journal:  Carcinogenesis       Date:  1996-09       Impact factor: 4.944

8.  Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.

Authors:  Thierry Lecomte; Jean-Marc Ferraz; Franck Zinzindohoué; Marie-Anne Loriot; David-Alexandre Tregouet; Bruno Landi; Anne Berger; Paul-Henri Cugnenc; Raymond Jian; Philippe Beaune; Pierre Laurent-Puig
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

9.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Authors:  Chariya Hahnvajanawong; Jariya Chaiyagool; Wunchana Seubwai; Vajarabhongsa Bhudhisawasdi; Nisana Namwat; Narong Khuntikeo; Banchob Sripa; Ake Pugkhem; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

10.  Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.

Authors:  Geraldine Perkins; Timothy A Yap; Lorna Pope; Amy M Cassidy; Juliet P Dukes; Ruth Riisnaes; Christophe Massard; Philippe A Cassier; Susana Miranda; Jeremy Clark; Katie A Denholm; Khin Thway; David Gonzalez De Castro; Gerhardt Attard; L Rhoda Molife; Stan B Kaye; Udai Banerji; Johann S de Bono
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more
  3 in total

1.  Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Authors:  Daniel L Hertz; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Meredith M Regan; Todd C Skaar; N Lynn Henry; Daniel F Hayes; Catherine H Van Poznak; James M Rae
Journal:  Mol Oncol       Date:  2015-07-29       Impact factor: 6.603

2.  Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.

Authors:  Nima C Emami; Lancelote Leong; Eunice Wan; Erin L Van Blarigan; Matthew R Cooperberg; Imelda Tenggara; Peter R Carroll; June M Chan; John S Witte; Jeffry P Simko
Journal:  Prostate       Date:  2016-11-30       Impact factor: 4.104

3.  Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.

Authors:  Elizabeth Smyth; Shenli Zhang; David Cunningham; Andrew Wotherspoon; Richie Soong; Clare Peckitt; Nicola Valeri; Matteo Fassan; Massimo Rugge; Alicia Okines; William Allum; Sally Stenning; Matthew Nankivell; Ruth Langley; Patrick Tan
Journal:  Clin Cancer Res       Date:  2017-10-02       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.